Merck Acquires Terns for $6.7 Billion to Expand Cancer Portfolio
Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, a move aimed at bolstering its presence in the blood cancer treatment market. The acquisition will provide Merck with access to Terns' portfolio of cancer therapies.